Lescrinier E
Rega Instituut, Katholieke Universiteit Leuven, Minderbroedersstraat 10--3000 Leuven.
Verh K Acad Geneeskd Belg. 2011;73(1-2):65-78.
Structural biologists focus on the structure of biomolecules. Several techniques are available to study the structure adopted by a biomolecule and unravel how this structure is related to its constitution and function. For their biological role in a functioning cell or organism, biomolecules interact with each other and/or rather small molecules in their environment. Drugs can exploit interaction with biomolecules to manipulate their biological function to obtain a therapeutic effect. Structure determination of biomolecules that (could) serve as therapeutic target is an important starting point in rational drug design. Once the structure of a biological target is known, a potential binding site for drugs and possible interactions at this site have to be identified. In the stage of drug design this information is a valuable input for modeling experiments. They can virtually scan libraries of compounds by docking them into the binding site. This strategy ranks potential ligands that can be chemically modified to optimize their interaction at the binding site ('lead optimization') in order to improve affinity and selectivity for the biomolecular target. Modeling can also be used to virtually 'build' new molecules starting from possible interactions and shape of the target binding site ('de novo design'). Structural biology can contribute in different stages of drug development to direct the process or optimize existing compounds.
结构生物学家专注于生物分子的结构。有几种技术可用于研究生物分子所采用的结构,并揭示这种结构与其组成和功能之间的关系。由于生物分子在功能正常的细胞或生物体中发挥生物学作用,它们会相互作用和/或与其环境中的小分子相互作用。药物可以利用与生物分子的相互作用来操纵其生物学功能以获得治疗效果。确定可作为治疗靶点的生物分子的结构是合理药物设计的重要起点。一旦知道了生物靶点的结构,就必须确定药物的潜在结合位点以及该位点可能的相互作用。在药物设计阶段,这些信息是建模实验的宝贵输入。他们可以通过将化合物对接至结合位点来虚拟筛选化合物库。这种策略对潜在配体进行排序,这些配体可以进行化学修饰以优化它们在结合位点的相互作用(“先导优化”),从而提高对生物分子靶点的亲和力和选择性。建模还可用于从靶点结合位点的可能相互作用和形状开始虚拟“构建”新分子(“从头设计”)。结构生物学可以在药物开发的不同阶段做出贡献,以指导这一过程或优化现有化合物。